November 22, 2017 / 7:22 AM / a month ago

BRIEF-Cerenis Therapeutics announces first patients enter TARGET study

Nov 22 (Reuters) - CERENIS THERAPEUTICS HOLDING SA:

* FIRST PATIENTS ENTER TARGET STUDY, RECENTLY INITIATED BY CERENIS THERAPEUTICS TO EVALUATE HDL NANOPARTICLES IN PATIENTS WITH ESOPHAGEAL CANCER

* ‍A TOTAL OF 10 PATIENTS WILL UNDERGO ALL STUDY PROCEDURES​

* ‍STUDY IS EXPECTED TO BE COMPLETED BY END OF Q2 2018 ​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below